1. "Gynecologic Medicine Service"
Formats
  1. Journal Article (1087)
  2. Meeting Abstract (890)
  3. Review (52)
  4. Book Section (46)
  5. Editorial (35)
  6. Guidelines (21)
  7. Correspondence (9)
  8. Miscellaneous (3)
  9. Research Letter (2)
  10. Book Whole (1)
Groups
  1. Gynecologic Medicine Service (2146)
  2. Solid Tumor Oncology Division (2146)
  3. Department of Medicine (2142)
  4. Gynecology Disease Management Team (1846)
  5. GDMT, Medicine (1828)
  6. Surgery (594)

More Groups

People
  1. Carol Aghajanian (607)
  2. Martee Hensley (289)
  3. Nadeem Abu-Rustum (288)
  4. Roisin O'Cearbhaill (271)
  5. Vicky Makker (263)
  6. Paul Sabbatini (262)

More People

Years
  1. 2025 (41)
  2. 2024 (167)
  3. 2023 (171)
  4. 2022 (209)
  5. 2021 (163)
  6. 2020 (203)

More Years

Publications
  1. Journal of Clinical Oncology (450)
  2. Gynecologic Oncology (418)
  3. International Journal of Gynecological Cancer (154)
  4. Annals of Oncology (116)
  5. Clinical Cancer Research (67)
  6. Cancer Research (55)

More Publications

Publishers
  1. Elsevier Inc. (542)
  2. American Society of Clinical Oncology (489)
  3. Lippincott Williams & Wilkins (181)
  4. American Association for Cancer Research (168)
  5. Oxford University Press (143)
  6. Nature Publishing Group (86)

More Publishers

Results (2146)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor-fusion protein, for treatment of recurrent/persistent endometrial cancer: GOG-0229N
    Meeting Abstract

    Makker, V.; Filiaci, V. L.; Chen, L. M.; Darus, C.; Kendrick, J. E.; Sutton, G.; Moxley, K.; Aghajanian, C.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Phase II, single stage, cohort expansion study of MK-2206 in recurrent endometrial serous cancer
    Meeting Abstract

    Konstantinopoulos, P.; Makker, V.; Barry, W. T.; Liu, J.; Horowitz, N. S.; Birrer, M. J.; Doyle, L. A.; Berlin, S. T.; Whalen, C.; Van Hummelen, P.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Phase II feasibility study of paclitaxel (T) with trastuzumab (H) and lapatinib (L) for node-negative, HER2-positive breast cancer (BC)
    Meeting Abstract

    Iyengar, N. M.; Fornier, M. N.; Sugarman, S.; Theodoulou, M.; Troso-Sandoval, T. A.; D'Andrea, G.; Drullinsky, P.; Fasano, J.; Gajria, D.; Goldfarb, S. B.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A phase 2 study of live-attenuated listeria monocytogenes cancer immunotherapy (ADXS11-001) in the treatment of persistent or recurrent cancer of the cervix (GOG-0265)
    Meeting Abstract

    Huh, W. K.; Brady, W. E.; Moore, K. N.; Lankes, H. A.; Monk, B. J.; Aghajanian, C.; Dizon, D. S.; Armstrong, D. K.; Thaker, P. H.; Fracasso, P. M.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Effect of enzalutamide (Enza) on androgen receptor (AR) positive (+) ovarian cancer
    Meeting Abstract

    Grisham, R. N.; Thapi, D.; Berman, T.; de Stanchina, E.; Zhou, Q.; Iasonos, A.; Iyer, G.; Aghajanian, C.; Spriggs, D. R.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A virtual consult service to optimize clinical trial participation in patients with metastatic breast cancer
    Meeting Abstract

    Cadoo, K. A.; Shah, P. D.; Charen, A. S.; Bromberg, J.; Comen, E. A.; D'Andrea, G.; Dang, C. T.; Gilewski, T.; Gucalp, A.; Lake, D.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Greater total dose and duration of treatment with bortezomib are associated with higher incidence of chalazion and other ocular side effects
    Meeting Abstract

    Ganesh, K.; Batlevi, C.; Zhang, Z. G.; Hassoun, H.; Lendvai, N.; Landau, H.; Moskowitz, C. H.; Caron, P.; Motzer, R.; Giralt, S. A.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • TRC105 (anti-endoglin antibody) in combination with bevacizumab (BEV) and as a single agent for platinum resistant ovarian cancer
    Meeting Abstract

    Garcia, A. A.; Makker, V.; Spitz, D. L.; Matei, D. E.; Nick, A. M.; Landen, C. N.; Alvarez, E. A.; Mendelson, D. S.; Strother, R. M.; Seon, B. K.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Correlation between Ca-125 and clinical disease progression in patients with ovarian cancer treated with bevacizumab: Analyses from 4 randomized trials
    Meeting Abstract

    Morales, L.; Burger, R. A.; Aghajanian, C.; Perren, T. J.; Pujade-Lauraine, E.; Moore, N.; Husain, A.
    International Journal of Gynecological Cancer (2014)

    Fulltext@MSK | Save
  • Randomized phase 2 evaluation of bevacizumab versus bevacizumab/fosbretabulin in recurrent ovarian, tubal or peritoneal carcinoma: A gynecologic oncology group study
    Meeting Abstract

    Monk, B.; Sill, M.; Walker, J.; DiSilvestro, P.; Sutton, G.; Tewari, K.; Pajon, E.; Martin, L.; Schilder, J.; Coleman, R.; more...
    International Journal of Gynecological Cancer (2014)

    Fulltext@MSK | Save